Under the Paperwork Reduction Act of 1995, no persons are required to resp to a collection of information unless it contains a valid OMB control number

INFORMATION DISCLOSURE			Application Number			10575814						
			Filing Date			2006-04-14						
			First N	First Named Inventor SAL		AH-DINE CHIBOUT						
		NT BY APPLICA ission under 37 CFR 1		Art Ur	nit					-		
(11011011	Jubin	ission under or or it	.55)	Exam	Examiner Name							
				Attorn	Attorney Docket Number 4-33			4-33318A				
					U.S.I	PATENTS				Remove		
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue E	Issue Date Name of Patentee or Applicant of cited Document		Relev	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear				
	1											
If you wisl	h to a	dd additional U.S. Pater	t citatio	n inform	ation pl	ease click	the A	dd button.		Add		
			U.S.P.	ATENT	APPLI	CATION P	UBLI	CATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date		Name of Patentee or Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear				
	1											
If you wisl	If you wish to add additional U.S. Published Application citation information please click the Add button. Add											
				FOREIG	SN PAT	ENT DOC	UME	NTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	i	Kind Code ⁴	Publication Date	n [Name of Patente Applicant of cited Document	e or	where Rel	or Relevant	
	1	EP0505135A				1992-09-2	- 1	MERCK & CO. INC	;			
	_	WO03035670				2000 05 /		THE REGENTS OF	FTHE			

2003-05-01

NON-PATENT LITERATURE DOCUMENTS

If you wish to add additional Foreign Patent Document citation information please click the Add button

CALIFORNIA

Add Remove

EFS Web 2.0.1

2

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10575814
Filing Date		2006-04-14
First Named Inventor	SALA	H-DINE CHIBOUT
Art Unit		
Examiner Name		
Attorney Docket Number		4-33318A

Examiner Initials*	Cite No	include name of the author (in CAPTIAL LETTERS), use of the structe (when appropriate), use of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	Тs
	1	CHEUNG M C ET AL, "Comparison of the effects of triphasic", Metabolism, Clinical and Experimental, vol. 48, no. 5, pp. 659-664, May 1999	
	2	IN ET AL, "Naturally cocurring mutations in the human 5-Lipoxygenase gene", Journal of Clinical Investigation, vol. 99, no.5, pp. 1139-1137, 1997	
	3	ARCHACKI STEPHEN R ET AL, "identification of new genes differentially expressed in coronary", Physiological Genomics, vol. 15, pp. 65-74, January 2004	
	4	MA JUN ET AL, "Gene profiling identifies secreted protein", Journal of Molecular and Cellular Cardiology, vol. 35, no. 8, pp. 983-988, August 2003.	
	5	YOU SUN-AH ET AL, "Proteomic approach to coronary atheroscierosis", Physiological Genomics, vol. 13, pp. 25-30, July 2003.	
	6	KOENIG W ET AL, "C-reactive protein, a sensitive marker of inflammation, predicts future", Circulation, American Heart Association, vol. 99, pp. 237-242, January 10, 1999	
	7	WILSON P.W.F.ET.AL, "Prediction of coronary heart disease using risk factor categories", Circulation, American Heart Association, vol. 97, pp. 1837-1847, 1988	
	8	WILSON PW F ET AL, "Established risk factors and coronary artery disease", American Journal of Hypertension, vol. 7, no. 7, part 2, pp. 78-128, July 1994	
	9	OCONNER CHRISTOPHER M ET AL, "Clinical characteristics and long-term outcomes of patients with heart failure,", The American Journal of Cardiology, vol. 86, no. 8, pp. 863-867, August 15, 2000	
14		Add	-

EXAMINER SIGNATURE					
Examiner Signature		Date Considered			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

18ee Knr. Codes of USPTO Petern Documents at wew USPTO_GOLV or MEPE 90.04. Teters from that assect the document, by the knowletic code (WIPO Standard ST3.) "For Impresses patient counters, he included on the year of the region or impresses to sense included." A find of counters by the appropriate symbols as indicated on the coopument under WIPO Standard ST3. 16 if possible, "Applicant is to place a check mark here if English language translations in state-for."

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99) Art Unit

Application Number		10575814	
iling Date		2006-04-14	
irst Named Inventor	SALAH-DINE CHIBOUT		
Art Unit			
xaminer Name			
Attorney Docket Number		4-33318A	

CERTIFICATION STATEMENT

Please see 37 CFR 1.97	and 1.98 to make t	the appropriate selection(s):
------------------------	--------------------	-------------------------------

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information sisclosure statement. Sea 37 CFF 1.97(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 13760, more than three months prior to the filing of the information disclosure statement Sea 37 CFR 13760, and the statement Sea 37 CFR 13760.

- See attached certification statement.

 Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- ☑ None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	Date (YYYY-MM-DD)	
Manual Polant	Desistantias Number	

This collection of information is required by 3T CPR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is the file and by the USPTO to process) an application. Conflorentality is governed by \$5 U.S. C. 12 and 3T CPR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Operatment of Commence, P. 0. Bott 1450, Alexandria, V.A.2311-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.A.2311-1450.

Privacy Act Statement

The Privacy Act of 1974 (P. L. 95.79) requires that you be given certain information in connection with your submission of the attached form reliable to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that. (1) the general authority for the collection of this information is SU S C. 2(b)(2); (2) furnishing of the information solicited is culturally, and (5) the principal purpose for which the information is used by the U.S. Patient and Trademan KOTile is to information, the U.S. Patient and Trademan KOTIle may not be able to process and/or examine your submission, which may result in farmination of proceedings or abandoment of the application or experization of the patient.

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires facilisative of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement necotiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, unsurant to 5 U.S.C. 552/a/m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be discbeed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an inspection of records conducted by GSA as part of that agency? responsibility to recommend improvements in records management practices and programs, under authority of 4U SC. 2904 and 2908. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make referentiations out and including the control of the control o
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 12(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application poen to public insepticions or an insuce patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.